What is HC Wainwright's Forecast for JSPR FY2029 Earnings?

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Stock analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Jasper Therapeutics in a research note issued to investors on Wednesday, January 8th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($10.81) per share for the year. HC Wainwright has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for Jasper Therapeutics' current full-year earnings is ($4.47) per share.

A number of other brokerages also recently commented on JSPR. JMP Securities restated a "market outperform" rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a research report on Monday. BMO Capital Markets began coverage on Jasper Therapeutics in a research note on Friday, December 6th. They issued an "outperform" rating and a $63.00 price target on the stock. Finally, Royal Bank of Canada dropped their price objective on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating on the stock in a report on Thursday. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $67.75.

Jasper Therapeutics Trading Up 0.9 %

Shares of NASDAQ:JSPR traded up $0.06 during midday trading on Friday, hitting $7.05. The stock had a trading volume of 2,449,654 shares, compared to its average volume of 1,818,043. Jasper Therapeutics has a 1 year low of $6.57 and a 1 year high of $31.01. The stock has a 50 day moving average price of $21.37 and a two-hundred day moving average price of $20.27. The company has a market capitalization of $105.76 million, a PE ratio of -1.49 and a beta of 2.18.

Hedge Funds Weigh In On Jasper Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its position in shares of Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company's stock valued at $47,000 after purchasing an additional 1,698 shares during the last quarter. Wolff Wiese Magana LLC purchased a new stake in Jasper Therapeutics in the 3rd quarter valued at approximately $59,000. MetLife Investment Management LLC grew its holdings in Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company's stock valued at $129,000 after buying an additional 3,873 shares during the last quarter. Jane Street Group LLC acquired a new stake in Jasper Therapeutics during the 3rd quarter valued at $251,000. Finally, Rhumbline Advisers purchased a new position in Jasper Therapeutics during the second quarter worth $300,000. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.